Synergistic Benzathine Analog Systems for Enhanced Inflammatory Disorder Treatment

The present inventive concept integrates benzathine analogs with advanced technologies like AI, IoT, blockchain, and nanomaterials to create a more effective and personalized treatment approach for inflammatory disorders, overcoming limitations of traditional therapies.

Inflammatory disorders, such as sepsis and pneumonia, remain a significant health burden despite existing treatments. The original patent disclosed benzathine analogs as a promising therapeutic approach, but their efficacy can be limited by variability in patient response and lack of personalized dosing. The new inventive concept addresses these limitations by combining benzathine analogs with synergistic technologies to enhance treatment outcomes.

The inventive concept encompasses systems and methods that integrate benzathine analogs with artificial intelligence (AI) for optimized dosage prediction, IoT-enabled devices for real-time patient monitoring, blockchain-based platforms for secure medical history management, and nanomaterial carriers for targeted drug delivery. For instance, Claim 1 describes a system comprising a benzathine analog and an AI module that predicts optimal dosage based on individual patient characteristics, ensuring more effective treatment. Claim 2 outlines a method that combines benzathine analog administration with IoT-enabled monitoring to adjust treatment regimens in real-time. Claim 3 details a blockchain-based platform for secure storage and sharing of medical history and treatment outcomes, facilitating personalized medicine. Claim 4 describes a machine learning-based approach for identifying novel benzathine analogs, and Claim 5 discloses a composition featuring a benzathine analog and a nanomaterial carrier for targeted delivery to immune effector cells.

The new claims introduce a synergistic combination of benzathine analogs with advanced technologies, which is not obvious from the original patent. The inventive concept's novelty lies in its integrated approach, which leverages the strengths of each component to create a more effective and personalized treatment system.

Alternative embodiments of the inventive concept could include integrating benzathine analogs with other AI algorithms, such as natural language processing or computer vision, to analyze patient data and predict treatment outcomes. Another variation could involve using different types of nanomaterial carriers or IoT devices to tailor the system to specific patient populations or treatment settings.

The synergistic benzathine analog systems have significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of inflammatory disorders such as sepsis and pneumonia. The market for these systems is substantial, with an estimated value of over $10 billion by 2025.